CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
venlafaxine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01611155
NCT01611155N/ACompleted

A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy

Mayo Clinic·interventional·Posted Jun 4, 2012·Updated Sep 26, 2019

In Brief

A clinical study evaluating venlafaxine, placebo, and 2 other interventions for Peripheral Neuropathy. Completed, enrolled 50 participants across 1 site.

Detailed Summary

You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 4, 2012
Enrollment StartFeb 17, 2012
Primary CompletionMar 7, 2014
Study CompletionSep 23, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.1 years ago

Interventions

venlafaxinedrug

Given PO

placebodrug

Given PO

questionnaire administrationother

Ancillary studies

quality-of-life assessmentother

Ancillary studies